Terrace Eye Centre is proud to be involved in a Phase 4 Diabetic Macular Oedema (DME) Study. Macular oedema is caused by vascular leakage and is associated with a number of diseases including diabetic retinopathy and retinal vein occlusive disease.
The clinical trial is an observational study of patients who have diabetic macular oedema and have had cataract surgery or are scheduled for it. Patients receive a sustained-release steroid treatment ( Dexamethasone intravitreal implant) once every 4 – 6 months and are monitored over a 12 month period. This new technology is an exciting advance for those who previously have required monthly injections.
Terrace Eye Centre has been recruiting patients for almost 12 months now onto the trial. With the recruitment phase coming to an end last week, Terrace Eye Centre is delighted to be named the number one site in Australia. Patients who have Diabetic Macular Oedema and who have been selected for this trial have benefited from early access to Ozurdex and the extended duration of action of this exciting new slow release technology. Terrace Eye Centre will continue to manage these patients over the next twelve months and the results of the study will then be collated and published. We are looking forward to seeing some promising results.